Redhill Biopharma Ltd. RDHL shares are trading higher Wednesday after the company was granted a patent for a method for eradicating helicobacter pylori infections in patients regardless of body mass index.
The Excitement:
Redhill Biopharma shares are moving on above-average trading volume Wednesday. According to data from sources, more than 7.27 million shares have already been traded in the session, compared to the stock’s 100-day average of 9.125 million shares.
In late December, RedHill Biopharma announced that two of its investigational drugs, opaganib and RHB-107 (upamostat), demonstrated robust synergistic effect when combined individually with remdesivir (Veklury), in a U.S. Army-funded and conducted Ebola virus in vitro study.
“Opaganib and RHB-107 are both novel, oral, host-directed, small molecule investigational drugs with demonstrated activity against multiple viral targets, including COVID-19, and are expected to be effective against emerging viral variants. This, together with their growing safety and tolerability databases, presents a compelling hypothesis for further study of their potential in treating Ebola virus,” said Reza Fathi, Ph.D., senior vice president of research and development at RedHill.
Related Development: What’s Happening with Spirit Airlines Stock?
RDHL Price Movement: According to sources, RedHill Biopharma shares are up 22% at $1.09 at the time of publication.
Image Courtesy: Emilian Danaila from Pixabay
